Abstract: Pharmaceutically acceptable compositions suitable for releasing magnesium ions to an organism, such as organic or inorganic magnesium salts or complexes thereof, are used to prevent and to treat neoplastic and autoimmune diseases, whose origin can be attributed to magnesium depletion. For the new therapeutic indications the magnesium based product, preferably magnesium pyrophosphate, is usually administered orally or parenterally, preferably in association with vitamin B6.

Abstract: An additive for stimulants, useful in particular to reduce the health-damaging effects of coffee beverages, contains one or several vitamins, dandelion root extract, and, if required, one or several mineral salts. The additive characterized in that it contains anise extract and adenosine.

Abstract: A method of treating headache is provided using a water soluble magnesium salt. Specifically, a method of treating a headache is provided for an individual having a serum ionized magnesium concentration of 0.44 mmoles/L to 0.53 mmoles/L and having at least one headache symptom by administering an amount of a water soluble magnesium salt sufficaent to inhibit at least one headache symptom in the individual within 24 hours and to raise the serum ionized magnesium concentration in the individual to within a normal ionized magnesium concentration range of 0.54 mmoles/L to 0.67 mmoles/L. Headache symptoms which may be inhibited include: pain, aura, photophobia, nausea, unilateral pain and phonophobia.

Abstract: Metal amino acid chelates for animals are beneficial for facilitating and promoting growth by increasing desired metallic ion uptake. The present invention is directed to a process for providing an animal fed additive by preparing metal amino acid chelates, and the metal amino acid chelate growth facilitator, promoter and enhancer prepared by the process.

Abstract: Compositions for the treatment and prevention of migraine or stress headaches wherein there is supplied a combination of potassium, magnesium and pyridoxine optionally in association with other nutrients and/or simple analgesics.

Abstract: A chemical agent for use in binding to and insolubilizing the solubilized products of fat digestion in order to prevent absorption of fat from the diet.

Abstract: The invention provides a synthetic bone precursor material comprising amorphous calcium phosphate and a constituent that inhibits the crystallisation of calcium hydroxyapatite to amorphous calcium phosphate. The synthetic bone precursor may comprise a material of formula CaxMgyPO4 wherein Mg acts as an inhibitor for crystallisation. Other crystallisation inhibitors such as pyrophosphate may be present. The inhibitor is capable of dissolving in physiological saline. Loss of inhibitor from the precursor allows crystallisation of hydroxyapatite. The invention relates to use of a synthetic bone precursor to form bone in vivo, by a transformation of the amorphous precursor material to crystalline hydroxyapatite bone material by the leaching action on inhibitory ions body fluids. it is envisaged that the material will be useful in facilitating bone repair, inducing bone formation or assisting in the attachment of prostheses.

Abstract: Various preparations for treating or relieving pain in a patient are disclosed wherein preparations containing caesium ions, preferably in the form of caesium chloride, and preferably also magnesium ions in the form of magnesium sulphate, are administered externally or internally to the patient. In one preferred embodiment a topical preparation is provided which consists of strips of microporous material (A) on each side of a plastics backing layer (B) impregnated with an aqueous solution containing caesium chloride and magnesium sulphate. In an alternative embodiment a cream preparation containing caesium chloride and magnesium sulphate is provided for external application to the patient.

Abstract: The invention is directed to a method of enhancing lean tissue mass in a subject by administering calcium to the subject, thereby enhancing the lean tissue mass in the subject. The invention is also directed to a method of enhancing bone mineral content in a physically active subject comprising administering calcium to the subject, thereby enhancing the bone mineral content in the subject. The invention is also directed to a method of enhancing bone mineral content and of enhancing lean tissue mass in a subject comprising administering calcium to the subject, thereby enhancing the bone mineral content and enhancing the lean tissue mass in the subject. The invention is further directed to a milk-free composition for enhancing bone mineral content and/or for enhancing lean tissue mass in a physically active subject, comprising an effective amount of calcium.

Abstract: Calcium carbonate liquid antacid compositions containing one or more pH adjusting agents to maintain the pH above 9.0, preferably above 9.5. The resultant antacid liquid possesses superior resistance to microbial attack and enhanced taste properties.

Abstract: The present invention provides a dialysis solution that contains amino acids for treating and/or preventing malnutrition in a peritoneal dialysis patient. The amino acid composition is optimized to minimize metabolic acidosis while normalizing amino acid plasma profiles.

Abstract: A scalp and hair treatment method and composition wherein the composition comprises deionized water, a vasodilator (such as ethyl nicotinate and/or capsicum extract), a magnesium salt, and a hydrolyzed protein. The composition can be applied on a monthly or bi-monthly basis to the scalp and hair for about 30 minutes and rinsed away with water.

Abstract: The present invention provides a dialysis solution that contains amino acids for treating and/or preventing malnutrition in a peritoneal dialysis patient. The amino acid composition is optimized to minimize metabolic acidosis while normalizing amino acid plasma profiles.

Abstract: The present invention relates to dietary supplements for supplementing the dietary needs of women and preventing or reducing life stage associated health risks during each of their principal adult life stages (pre-perimenopause, perimenopause and menopause, or post-menopause).

Abstract: The invention relates to a pharmaceutical composition for treating the symptoms of vulvitis and vulvovaginitis which comprises folic acid, panthenol and/or allantoin, protein hydrolysate or casein hydrolysate, lactose or dextrose, lactic acid, magnesium sulfate and sodium chloride or ammonium chloride in the form of suppositories, ointments, solutions or sprays and a method of use thereof.

Abstract: A composition for the treatment of premenstrual syndrome comprising an effective amount of calcium, magnesium, an analgesic and a diuretic sufficient to reduce the symptoms of premenstrual syndrome.

Abstract: A method of making poultice by mixing together water, fine mineral powder, vinegar, herbal liniment solution, and hydrated magnesium sulfate (also known as Epsom salt) to produce a poultice capable of being applied to muscles, joints, or both which may be sore, injured, or both.

Abstract: An absorbable magnesium composition is provided. The absorbable magnesium composition includes a magnesium salt in a liposomal material encapsulating the magnesium salt. A method of using as well as a method of preparing the magnesium composition of the present invention is also provided.

Abstract: Agglomerated psyllium husk comprising edible acid uniformly dispersed throughout the agglomerating coating. Preferred are maltodextrin-containing agglomerates of psyllium husk comprising citric acid uniformly dispersed throughout the maltodextrin coating. This agglomerated psyllium husk has improved mixability and dispersibility in liquids.

Abstract: A calcium ion containing composition comprising a water in oil emulsion having a dispersed aqueous phase and a continuous oil phase, which composition is orally administerable and palatable to cows without causing lesions of the stomach and which composition is effective in preventing milk fever, said composition further comprising a calcium salt which is dissolved in the aqueous phase to form a calcium ion containing aqueous phase solution, the calcium in the composition, calculated as free calcium ion, comprising 10 to 20 percent by weight of the composition, said composition further including from 0.5 to 10 percent oil soluble non-ionic emulsifier. The invention also includes the method of orally administering the composition to cows to treat milk fever.

Abstract: The invention relates to a process for the preparation of a tablet or dragee composition containing a moisture-, heat- and light-sensitive compounds having monoclinic crystalline structure as active ingredients, which comprises homogenizing the active ingredient with 0.2 to 1.5 parts by weight of an anhydrous alkaline earth metal salt and 0.5 to 2.5 parts by weight of microcrystalline cellulose calculated for the active ingredient and optionally with one or more pharmaceutically acceptable carrier(s) and/or additive(s) and compressing the homogeneous mixture obtained to tablets in a manner known per se and, if desired, coating the tablet thus obtained in a manner known per se.

Abstract: A procaine acid addition salt, wherein the acid is attached to the diethylamino nitrogen, is complexed with a biologically active organic acid such as a vitamin acid, essential unsaturated fatty acid, C.sub.4 to C.sub.6 hydroxycarboxylic acid or alpha amino acid in stoichiometric ratios of organic acid to procaine acid addition salt to form a double salt complex wherein the organic acid attaches to the p-amino nitrogen. Such double salt complexes protect the procaine molecule from cholinesterase hydrolysis when orally administered to warm blooded animals allowing the complex to be carried intact to the site of damaged cells and across the cell membrane where the double salt complex is disassociated in the cell releasing the organic acid and procaine for cellular repair and regeneration. Procaine hydrochloride is the preferred procaine salt. Preferred acids are citric and vitamin acids including nicotinic acid, ascorbic acid, biotin and folic acid.

Abstract: Psyllium husk-containing drink mix compositions comprising small particle size psyllium husk and edible, water soluble salts. The edible, water soluble salts are present at a level sufficient to reduce the gellation rate of the psyllium husk when dispersed in an aqueous solution.

Abstract: Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias, such as AD. The onset and progression of dementia are diagnosed and monitored by following changes in the relative concentrations of two forms of albumin in either serum or CSF. The onset and progression of dementia are controlled and memory loss is impeded or the impairment of memory is improved by dietary supplementation or the administration of Mg.

Abstract: Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias, such as AD. The onset and progression of dementia are diagnosed and monitored by following changes in the relative concentrations of two forms of albumin in either serum of CSF. The onset and progression of dementia are controlled and memory loss is impeded or the impairment of memory is improved by dietary supplementation or the administration of Mg.

Abstract: A pharmaceutical composition comprises magnesium oxide, hydroxide or a non-toxic salt of magnesium in a slow-release carrier; this material may be combined with or co-prescribed with a diuretic or cardiac glycoside or adrenergic receptor blocking agent or a calcium antagonist for the treatment of hypertension or angina pectoris.